KeraVet Bio completes initial clinical studies – the results are in!

KeraVet Bio has completed initial clinical studies on the new wound care product KeraVet Gel. These studies show the significant clinical benefit KeraVet Gel provides to reduce licking behavior and to positively support improved healing outcomes in dogs and cats.

In this randomized controlled clinical trial, 34 healthy dogs and 12 healthy cats underwent either an ovariohysterectomy or orchiectomy procedure. Additionally, 6 healthy dogs received a repeat tape-strip insult to both forelimbs. Wounds were treated with either KeraVet Gel or Triple Antibiotic Ointment.

These studies showed that dog wounds treated with KeraVet Gel exhibited significantly less edema and chronic inflammation than wounds treated with Triple Antibiotic Ointment. For cat wounds treated with KeraVet Gel, they exhibited significantly less edema than wounds treated with Triple Antibiotic Ointment.

Results indicate that KeraVet Gel may decrease the wound inflammatory response, allowing for better wound outcomes while reducing destructive licking behavior.  Additional studies are scheduled to evaluate KeraVet Gel treatment of dermatological conditions and further support the ability to reduce the need for an E-collar. To review the complete abstract, click here.

*All KeraVet Bio animal clinical testing is non-terminal.

*Complete study details will be available upon publication.